Lacerta Therapeutics, Inc. a gene therapy company dedicated to the discovery and development of AAV-based gene therapies, has appointed Min Wang, PhD, JD and Marc Wolff to its Board of Directors.
Dr. Min Wang has over 20 years of experience in the biotech space where she has operated as a business and legal advisor to the board and senior management at private and publicly traded companies through different phases of their organizational lifecycle. Dr. Wang most recently served as COO at Monte Rosa Therapeutics, where she held broad management responsibilities for key corporate functions. Previously, Dr. Wang served as COO of BlueRock Therapeutics through its acquisition by Bayer in 2019. Prior to BlueRock, Dr. Wang held the position of Senior VP, General Counsel and Corporate Secretary of Agios Pharmaceuticals. Earlier in her career, Dr. Wang served in roles of increasing responsibility in legal and IP functions at Genentech and Merck. Dr. Wang received her PhD in Organic Chemistry from Brown University and a JD from Fordham University School of Law.
“Min’s extensive knowledge and expertise in drug and corporate development will serve Lacerta well as we look to become a leader in AAV-gene based therapies and we are privileged to welcome her to our board,” stated Edgar Rodriguez-Lebron, PhD, Lacerta’s President and CEO.
Marc Wolff brings more than 23 years of experience in the life sciences industry in various management and finance leadership roles. Mr. Wolff is currently CEO at Calviri, a fully integrated healthcare company whose mission is to provide a broad spectrum of therapeutic vaccines and early diagnostics that prevent and treat cancer. Prior to joining Calviri, Mr. Wolff served as COO and CFO of Aldevron where he played a key role in scaling the company through exponential growth, enabling Aldevron’s clients to access essential GMP materials for their novel applications in gene and cell therapy. Prior to Aldevron, Mr. Wolff was EVP and CFO of Sancilio Pharmaceuticals, where he played a key role in leading the company through its IPO process in 2015. Mr. Wolff received his Master’s in Management and International Finance from Reims Management School.
“We are very excited to have Marc join our board during this important time of accelerated growth and expansion at Lacerta,” said Dr. Rodriguez-Lebron. “His substantial knowledge and insight will be invaluable as we mature our platforms and begin to position ourselves in the market.”
Dr. Wang and Mr. Wolff will join Dr. Jackson Streeter, Lacerta’s Chairman, Joe Zenkus, Senior Vice President at Sarepta Therapeutics and Dr. Rodriguez-Lebron on Lacerta’s Board.
About Lacerta Therapeutics
Lacerta Therapeutics, Inc. is focused on exploiting our proprietary capsid technology and scalable manufacturing platform to advance AAV-based therapies via three primary approaches: gene replacement, gene modulation and novel vectorization of antibodies.